MDG1 — Medigene AG Income Statement
0.000.00%
Last trade - 00:00
- €57.72m
- €44.66m
- €31.64m
- 26
- 78
- 70
- 61
R2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.75 | 10.6 | 8.75 | 11 | 31.6 |
Cost of Revenue | |||||
Gross Profit | 6.91 | 10.2 | 7.46 | 9.63 | 29.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 30.3 | 30.8 | 37.4 | 21 | 40.4 |
Operating Profit | -22.5 | -20.2 | -28.7 | -9.98 | -8.73 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -21.7 | -19.9 | -28.4 | -10.3 | -9.37 |
Provision for Income Taxes | |||||
Net Income After Taxes | -21.2 | -20 | -28.9 | -9.98 | -8.33 |
Net Income Before Extraordinary Items | |||||
Net Income | -21.2 | -20 | -28.9 | -9.98 | -8.33 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21.2 | -20 | -28.9 | -9.98 | -8.33 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.768 | -0.813 | -1.12 | -0.406 | -0.339 |
Dividends per Share |